Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239678 | 1.00 | TYMP (0.58) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL4826069 | 1.00 | TYMP (0.58) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL6905301 | 1.00 | TYMP (0.58) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL22367653 | 0.94 | TYMP (0.65) | TYMPHIF1ASLC29A1ADORA3 | |
| SCHEMBL532504 | 0.91 | HIF1A (0.53) | ADORA1HIF1ASLC29A1PRKAG1PRKAA1 | |
| SCHEMBL18486296 | 0.89 | TYMP (0.56) | TYMPSLC29A1ADORA3 | |
| SCHEMBL14208930 | 0.89 | TYMP (0.45) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL22984001 | 0.89 | TYMP (0.58) | TYMP | |
| SCHEMBL3824088 | 0.89 | TYMP (0.58) | TYMP | |
| SCHEMBL21044306 | 0.89 | TYMP (0.58) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2415776-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-7795238-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-6787526-B1 | AND INTERFERON | IDENIX PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | disclosed |
| EP-1431304-A2 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | Idenix (Cayman) Limited (KY) | 2004-06-23 | — | — | EP | disclosed |
| US-20030225028-A1 | 2'-deoxy-beta-L-erythropentofuranonucleoside or a salt or prodrug thereof | GOSSELIN GILLES (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030220290-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B | CENTRE NATIONAL DA LA RESERCHE SCIENTIFIQUE | 2003-11-27 | — | — | US | disclosed |
| US-6596700-B2 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | IDENIX PHARMACEUTICALS INC. | 2003-07-22 | — | — | US | disclosed |
| US-6569837-B1 | Administering 2'-deoxy-beta-L-erythro-pentofuranonucleoside alone or with another anti-hepatitis B agent such as 3TC (beta-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane); use of beta-l-thymidine (telbivudine) | IDENIX PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| US-6566344-B1 | Administering beta-L-2'-deoxycytidine compound for therapy of hepatitis B virus infection | IDENIX PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-6444652-B1 | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B | NOVIRIO PHARMACEUTICALS LIMITED (CY) | 2002-09-03 | — | — | US | disclosed |
| US-6395716-B1 | Antivirals such as telbivudine | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2002-05-28 | — | — | US | disclosed |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | NOVARTIS AG (CH) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | TYMP 9/4885ADORA1 282/4885HIF1A 3597/4885 |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | DCTD, DUT, DPYD | TYMP 4/4885ADORA1 536/4885HIF1A 2677/4885 |
| US-20030225028-A1 | 2'-deoxy-beta-L-erythropentofuranonucleoside or a salt or prodrug thereof | ATIC, DUT, GART | TYMP 7/4885ADORA1 312/4885HIF1A 3506/4885 |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | TYMP 9/4885ADORA1 282/4885HIF1A 3597/4885 |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | TYMP 9/4885ADORA1 282/4885HIF1A 3597/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | TYMP 9/4885ADORA1 282/4885HIF1A 3597/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | TYMP 9/4885ADORA1 282/4885HIF1A 3597/4885 |
| US-20030220290-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B | DUT, PNP, ATIC | TYMP 7/4885ADORA1 280/4885HIF1A 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.